Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01700439 · ClinicalTrials.gov registry record · NA

Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

A NA study, sponsored by Edwards Lifesciences.

Completed
Registry status
NA
Development phase
934
Enrollment target

NCT01700439: Completed NA study, sponsored by Edwards Lifesciences.

NCT01700439 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 934 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01700439, a NA study, has completed, sponsored by Edwards Lifesciences.

COMPLETED
Registry status
NA
Development phase
934 participants
Enrollment target

Study Summary

The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.

Primary Outcome

Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:\[(Number of late adverse events/sum of late patient years) x 100\]

Interventions

  • DEVICE EDWARDS INTUITY valve

Trial Details

FieldValue
Enrollment Target 934 participants
Start Date 2012-09-26
Est. Completion 2021-05-26
Phase NA
Edwards Lifesciences

57 total trials

What the finished NCT01700439 record still lists

NCT01700439 is an interventional study that assigns participants to a tested intervention. The registered 934 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 1 intervention - of which EDWARDS INTUITY valve is the first listed.

NCT01700439 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01700439 about?

NCT01700439 is a clinical study titled "Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve". The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.

What is the current status of trial NCT01700439?

This trial is currently completed. It is a NA study. The enrollment target is 934 participants. The study started on 2012-09-26. Estimated completion is 2021-05-26.

What interventions are being tested in trial NCT01700439?

The interventions under investigation include: EDWARDS INTUITY valve (DEVICE).

Who is sponsoring clinical trial NCT01700439?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01700439's enrollment target sits among peer trials

934 123rd of 2000 higher than 1,878 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04626635 · 933 participants · Phase 1

    A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

  • NCT05519007 · 936 participants · NA

    Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

  • NCT05216432 · 930 participants · Phase 1

    First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  • NCT06932029 · 930 participants · NA

    SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01700439, the US trial registry maintained by the National Library of Medicine. NCT01700439 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.